Date: 2015-10-14
Type of information: Product acquisition
Compound: trabedersen
Company: Isarna Therapeutics (Germany) Autotelic (USA - CA)
Therapeutic area:
Type agreement: product acquisition
Action mechanism: antisense oligodeoxynucleotide. Trabedersen (AP 12009) is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human Transforming Growth Factor beta 2 (TGF-beta-2), which is applied intratumorally. This gene-silencing substance inhibits this growth factor at its translational level. Trabedersen has been granted orphan designation for three tumor indications: high grade glioma (US, EU), pancreatic cancer (US, EU) and malignant melanoma (US).
Disease:
Details: * On October 14, 2015, Isarna Therapeutics, the leader in transforming growth factor beta (TGF-ß) isoform targeted antisense therapeutics, and Autotelic, a specialist in therapeutic drug monitoring and development, announced an asset sale and purchase agreement for trabedersen, Isarna’s TGF-ß2 antisense oligonucleotide. Autotelic acquires full and worldwide rights to develop trabedersen, which had previously reached Phase 3 clinical evaluation to treat recurrent high-grade glioma. Autotelic utilizes therapeutic drug monitoring to achieve consistent drug levels benefiting both efficacy and toxicity in multiple indications. The company’s leadership has long-standing experience in the development of cancer therapies as part of the team that led the early development of Abraxane®, a protein-bound paclitaxel compound approved by the FDA and EMA for the treatment of solid tumors, which was acquired by Celgene in 2010 when it merged with Abraxis BioScience.
Subsequent to Abraxis, the team formed Igdrasol Inc. to develop next generation Abraxane®. Igdrasol recently was acquired by NantPharma in a deal that could be worth as much as $1.3 billion.
Financial terms: No financial details of the agreement have been disclosed.
Latest news:
